<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178876</url>
  </required_header>
  <id_info>
    <org_study_id>2690</org_study_id>
    <nct_id>NCT04178876</nct_id>
  </id_info>
  <brief_title>Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( CLESS)</brief_title>
  <acronym>CLESS</acronym>
  <official_title>Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy: Impact on Ovarian Reserve.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare two different laparoscopic surgical techniques
      (endometrioma stripping vs ethanol sclerotherapy) in terms of ovarian reserve (AMH levels),
      recurrence rate and pain relief.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with pelvic pain (VAS score≥4) and ultrasound diagnosis of endometrioma &gt; 4cm
      candidate to surgical removal of endometrioma will be randomized into 2 group. One Group will
      undergo laparoscopical stripping technique; the other one will undergo laparoscopic
      aspiration and sclerotherapy using 95% ethanol.

      The women will be introduced with both operative options and they will be informed about the
      randomization . After an elaborate explanation about the study they will sign an informed
      consent form. the following data will be collected prior the operation: age, gravity &amp;
      parity, operative history, general medical history, the cyst size, AMH (Anti Mullerian
      Hormone), symptoms related to endometriosis (through VAS score), fertility history including
      any fertility treatment in the past and planned pregnancy after the operation.

      The laparoscopy will take place in Fondazione Policlinico Gemelli IRCSS, Roma. in the study
      group the cyst content will be aspirated and flushed with normal saline. 95% sterile ethanol
      will be instilled into the cyst through a Nelathon catheter. Ethanol will be left in the cyst
      for 15 min then aspirated as completely as possible following normal saline flushing. In the
      control group we will follow the standard treatment which is cystectomy.

      The women will be followed at 1 , 3 , 6 and 12 months after the surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>impact on ovarian reserve, in terms of reduction of serum AMH levels</measure>
    <time_frame>up to 12 months after the laparoscopy</time_frame>
    <description>The AMH levels will be evaluated 1 month before the surgery and 1, 6 and 12 months after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endometrioma recurrence rate for the two surgical techniques</measure>
    <time_frame>up to 12 months after the laparoscopy</time_frame>
    <description>Ultrasound examination that demonstrate the presence/lack of ovarian cyst with sonographic features of endometrioma in the ovary where the procedure took place.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain relief after surgery</measure>
    <time_frame>up to 12 months after the laparoscopy</time_frame>
    <description>The severity of pelvic pain , assessed using a visual analogue scale with no-pain classified as 0 and worst imaginable pain as 10.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Endometrioma</condition>
  <arm_group>
    <arm_group_label>Aspiration and Sclerotherapy of endometriomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas</description>
  </arm_group>
  <arm_group>
    <arm_group_label>laparoscopic stripping technique</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cystectomy of endometriomas during laparoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ethanol sclerotherapy</intervention_name>
    <description>Endometrioma laparoscopic aspiration and sclerotherapy using 95% ethanol</description>
    <arm_group_label>Aspiration and Sclerotherapy of endometriomas</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stripping technique</intervention_name>
    <description>Endometrioma laparoscopic cystectomy</description>
    <arm_group_label>laparoscopic stripping technique</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between 18-35 years old

          -  Women with ultrasound diagnosis of ovarian endometrioma ≥4cm (with or without deep
             infiltrating endometriosis)

          -  History of dysmenorrhea and/or chronic pelvic pain

          -  candidates for elective laparoscopy due to endometriosis.

        Exclusion Criteria:

          -  - Previous surgery for ovarian endometriosis

          -  Evidence of premature ovarian failure (follicle stimulating hormone ≥40 international
             units/L)

          -  Endocrinal disorders that might affect ovarian function (e.g., polycystic ovary
             syndrome, thyroid dysfunction, hyperprolactinemia)

          -  Ultrasound suspicious of ovarian malignant disease according IOTA criteria

          -  endometrial cyst &lt; 4 cm. • ethanol sensitivity.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This is a Gynecological study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Scambia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Gemelli, IRCSS Università Cattolica del Sacro Cuore, Roma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandra De Cicco Nardone, MD</last_name>
    <phone>+393428235829</phone>
    <email>alessandradecicco@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra De Cicco Nardone, MD</last_name>
      <email>alessandradecicco@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Sweed MS, Makled AK, El-Sayed MA, Shawky ME, Abd-Elhady HA, Mansour AM, Mohamed RM, Hemeda H, Nasr-Eldin EA, Attia NS, Eltaieb E, Allam H, Hussein A. Ovarian Reserve Following Laparoscopic Ovarian Cystectomy vs Cyst Deroofing for Endometriomas. J Minim Invasive Gynecol. 2019 Jul - Aug;26(5):877-882. doi: 10.1016/j.jmig.2018.06.022. Epub 2018 Sep 5.</citation>
    <PMID>30193971</PMID>
  </reference>
  <reference>
    <citation>Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis. Fertil Steril. 2017 Jul;108(1):117-124.e5. doi: 10.1016/j.fertnstert.2017.05.015. Epub 2017 Jun 1. Review.</citation>
    <PMID>28579409</PMID>
  </reference>
  <reference>
    <citation>Messalli EM, Cobellis G, Pecori E, Pierno G, Scaffa C, Stradella L, Cobellis L. Alcohol sclerosis of endometriomas after ultrasound-guided aspiration. Minerva Ginecol. 2003 Aug;55(4):359-62.</citation>
    <PMID>14581861</PMID>
  </reference>
  <reference>
    <citation>García-Tejedor A, Castellarnau M, Ponce J, Fernández ME, Burdio F. Ethanol sclerotherapy of ovarian endometrioma: a safe and effective minimal invasive procedure. Preliminary results. Eur J Obstet Gynecol Reprod Biol. 2015 Apr;187:25-9. doi: 10.1016/j.ejogrb.2015.02.004. Epub 2015 Feb 16.</citation>
    <PMID>25739052</PMID>
  </reference>
  <reference>
    <citation>Kovačević VM, Anđelić LM, Mitrović Jovanović A. Changes in serum antimüllerian hormone levels in patients 6 and 12 months after endometrioma stripping surgery. Fertil Steril. 2018 Nov;110(6):1173-1180. doi: 10.1016/j.fertnstert.2018.07.019.</citation>
    <PMID>30396562</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Scambia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>endometrioma</keyword>
  <keyword>ethanol</keyword>
  <keyword>sclerotherapy</keyword>
  <keyword>aspiration</keyword>
  <keyword>ovarian reserve</keyword>
  <keyword>endometriosis</keyword>
  <keyword>AMH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>data will become available following publication.</ipd_time_frame>
    <ipd_access_criteria>To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

